Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Autoantibody development under treatment with immune checkpoint inhibitors.

de Moel EC, Rozeman EA, Kapiteijn EHW, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JBAG, Toes REM, van der Woude D.

Cancer Immunol Res. 2018 Nov 13. pii: canimm.0245.2018. doi: 10.1158/2326-6066.CIR-18-0245. [Epub ahead of print]

PMID:
30425107
2.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM.

Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10.

3.

Neoantigen landscape dynamics during human melanoma-T cell interactions.

Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH.

Nature. 2016 Aug 4;536(7614):91-5. Epub 2016 Jun 27.

PMID:
27350335
4.

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.

van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ.

Ophthalmology. 2015 Sep;122(9):1907-16. doi: 10.1016/j.ophtha.2015.05.027. Epub 2015 Jun 26.

PMID:
26123090

Supplemental Content

Loading ...
Support Center